# JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Source: https://onco.cc/trials/nct06846437/  
OnCo record `nct06846437` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing JSKN003 in HER2-positive breast cancer, now recruiting.

## Summary

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer is a phase 3 interventional study registered as NCT06846437, led by Shanghai JMT-Bio, and recruiting on the registry. Official title: A Randomised, Controlled, Open-Label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Subjects. Planned enrolment is 228 participants (estimated). The study started in 2025-02-18 and primary completion is expected in 2026-10-13. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06846437
- Phase: 3
- Setting: A Randomized, Controlled, Open-Label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Subjects
- Sponsor: Shanghai JMT-Bio
- Enrolled: 228

## Sources

- ClinicalTrials.gov NCT06846437: https://clinicaltrials.gov/study/NCT06846437

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [JSKN003](https://onco.cc/drugs/jskn003/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct06846437.json